Do you have solid tumor of the lung or esophagus? Have the standard treatments for your condition been ineffective or not tolerable? If so, you may be eligible to participate in an early phase research study of the investigational drug YL201 as a possible treatment for advanced solid tumors.

Do you have incurable, metastatic, or recurrent head and neck squamous cell carcinoma? If so, you may be able to participate in a study to evaluate the addition of the anti-cancer drug, Cetuximab, to standard of care treatment.

Do you have incurable, metastatic/recurrent head and neck squamous cell carcinoma? If so, you may be able to take part in a study to see if a new drug called petosemtamab is effective. We want to see if petosemtamab works better than the treatments doctors usually use for head and neck squamous cell carcinoma. Compensation provided.

In this study, we want to asses the long-term safety of using a virus to deliver a gene, AAV2-hAQP1, and how effective this gene is at treating dry mouth in people who have received radiation therapy for head and neck cancer.

This study will evaluate BAY 3375968 as a new immunotherapeutic agent in advanced solid tumor settings of high medical need.

Do you have With Locally Advanced or Metastatic Solid Tumors of the Head or Neck? If so, you may be able to participate in a research study to to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizumab (Keytruda®).

In this study, we want to learn about a new tool that helps cancer patients make decisions. We also want to understand how patients and doctors communicate when choosing treatments.

Have you been diagnosed with cancer. If so, you may be able to take part in a research study looking to improve cancer care for patients whose treatment outcomes have led to challenges in their quality of life.

Have you been histologically or cytologically confirmed to have Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma that is considered incurable by local therapies? If so, you may be able to participate in a research study seeking to find out if Amivantamab Monotherapy and/or Amivantamab in Addition to Standard of Care Therapeutic Agents can be an effective traetment.

Are you interested in improving your physical health and wellbeing during or after cancer treatment? If so, our free 12- week exercise program might be a good fit for you! We are creating a registry of adults with a cancer diagnosis who have gone through our program.